Announcement on Abnormal Fluctuations in Stock Trading
The company and its entire board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false representations, misleading statements, or material omissions.
Special Reminder:
-
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) Eptuna injection has not yet been listed for sale. The listing application for the Company's Eptuna injection for the treatment of type 2 diabetes is currently under review. The Company is supplementing information as requested by the Drug Evaluation Center of the National Medical Products Administration. The review is not yet complete. It remains uncertain whether Eptuna will ultimately be approved for listing and when. There are many types of drugs for treating type 2 diabetes, and GLP-1RA is one of them. Even if Eptuna is launched in the future, it will face high market competition risks, and its profitability is highly uncertain.
-
The Company's application for clinical trials of Eptuna injection for weight loss has been approved by the National Medical Products Administration, but clinical trials have not yet officially commenced. Even if Eptuna undergoes clinical trial research for weight loss, there are many uncertainties regarding the progress and results of the clinical trials, as well as the future market competition landscape.
-
The research and development registration of Eptuna is led by the Company's holding subsidiary, Changshan Kaijie Health Biotechnology Research and Development (Hebei) Co., Ltd. (hereinafter referred to as Changshan Kaijie Health). The Company holds a 51% stake in Changshan Kaijie Health. The portion of its net profit attributable to the listed company's shareholders is 51%, while the portion attributable to minority shareholders is 49%. If Changshan Kaijie Health achieves profitability in the future, the Company will not be entitled to its entire net profit.